Gilead Sciences (GILD) Stock Forecast & Price Target

Gilead Sciences
Bull Case

Here are some ways that investors could benefit from investing in Gilead Sciences, Inc.:

• Gilead Sciences, Inc. recently announced a significant collaboration with Vir Biotechnology to discover and develop three PRO-XTEN dual-masked T-cell engagers targeting solid tumor-associated antigens, a move that strengthens the company's oncology pipeline and diversifies its growth beyond its established HIV and hepatitis franchises.
• The stock is currently trading at $157.37, having recently hit a new 52-week high of $160.51, indicating strong momentum and investor confidence as the company clears previous technical peaks and attracts attention from momentum investors.
• Wall Street analysts maintain a consensus rating of Moderate Buy with a target price of $159.33, with recent positive actions including HSBC raising its price objective to $175.00 and Needham & Company LLC reiterating a buy rating with a $170.00 target, reflecting constructive sentiment on the company's earnings outlook.
• Investors can benefit from a dividend yield of 2.22%, supported by a recent quarterly dividend payment of $0.82 per share, which provides a steady income stream and highlights the company's commitment to shareholder returns despite its growth initiatives.
• The company demonstrated strong financial performance in its most recent quarterly report, with revenue of $7.80 billion exceeding analyst estimates of $7.40 billion and representing a 10.6% year-over-year increase, while also beating consensus EPS estimates by $0.50.